Serum Apoptotic Caspase Activity in Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease

Journal of Clinical Gastroenterology

Volumn 44, Issue 4, 2010, Pages e87-e95

  Papatheodoridis, George V ^a   Hadziyannis, Emilia ^a   Tsochatzis, Emmanuel ^b   Georgiou, Anastasia ^b   Kafiri, Georgia ^a   Tiniakos, Dina G ^a   Margariti, Katerina ^a   Manolakopoulos, Spilios ^a   Manesis, Emanuel K ^a   Archimandritis, Athanasios J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b GR 546 42 T   (Greece)

Author keywords

Caspase; Cytokeratin; Fatty liver; Fibrosis; Hepatitis C; Keratin; M30; Steatohepatitis; Steatosis

Indexed keywords

CASPASE; CYTOKERATIN 18;

ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SERUM;

ADOLESCENT; ADULT; AGED; APOPTOSIS; BIOLOGICAL MARKERS; CASPASES; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KERATIN-18; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 77949967857     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181c0945a     Document Type: Article

References (37)

1. Dusheiko GM. The natural course of chronic hepatitis C: implications for clinical practice. J Viral Hepat. 1998;5(suppl 1):9-12.
2. National Institute of Health Consensus Development Conference Statement. Management of hepatitis C: 2002 - June 10 to 12, 2002. Hepatology. 2002;36(suppl 1):S3-S20.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
4. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356-1362.
5. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology. 2006;43:S31-S44.
6. Van Eyken P, Desmet VJ. Cytokeratins and the liver. Liver. 1993;13:113-122.
7. Ku NO, Liao J, Omary MB. Apoptosis generates stable fragments of human type I keratins. J Biol Chem. 1997;272:33197-33203.
8. Leers MPG, Kolgen W, Bjorklund V, et al. Immunohistochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999;187:567-572.
9. Bantel H, Lugering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology. 2004;40:1078-1087.
10. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27-33.
11. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut. 2008;57:500-506.
12. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
13. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474.
14. Kleiner DE, Brunt EM, Van NM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
15. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005;54:1024-1033.
16. Bantel H, Ruck P, Gregor M, et al. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol. 2001;80:230-239.
17. ali-Furet NL, Chami M, Houel L, et al. Hepatitis C virus core triggers apoptosis in liver cells by inducing ER stress and ER calcium depletion. Oncogene. 2005;24:4921-4933.
18. Nomura-Takigawa Y, Nagano-Fujii M, Deng L, et al. Non-structural protein 4A of Hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis. J Gen.Virol. 2006;87:1935-1945.
19. Deng L, Adachi T, Kitayama K, et al. Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol. 2008;82:10375-10385.
20. Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002;36:973-977.
21. Seidel N, Volkmann X, Langer F, et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology. 2005;42:113-120.
22. Walsh MJ, Vanags DM, Clouston AD, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology. 2004;39:1230-1238.
23. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta. 2002;1585:202-212.
24. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40:185-194.
25. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-597.
26. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol. 2007;102:634-641.
27. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004;39:273-278.
28. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125:437-443.
29. Feldstein AE, Canbay A, Guicciardi ME, et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol. 2003;39:978-983.
30. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-Cytokerat18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50:1072-1078.
31. Diab DL, Yerian L, Schauer P, et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol. 2008;6:1249-1254.
32. Yilmaz Y, Dolar E, Ulukaya E, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol. 2007;13:837-844.
33. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.
34. Chrysanthos NV, Papatheodoridis GV, Savvas S, et al. Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol. 2006;18:389-396.
35. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that indentifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854.
36. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2005;11:255-259.
37. Trombini P, Piperno A. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons. J Hepatol. 2007;46:549-552.